Ticker Details
Incyte Corp. Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.
IPO Date:	November 4, 1993
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$21.68B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.91 | 2.14%
Avg Daily Range (30 D):	$1.52 | 1.54%
Avg Daily Range (90 D):	$1.53 | 1.55%

Institutional Daily Volume
Avg Daily Volume:	1.34M
Avg Daily Volume (30 D):	1.16M
Avg Daily Volume (90 D):	1.23M

Trade Size
Avg Trade Size (Sh.):	102
Avg Trade Size (Sh.) (30 D):	45
Avg Trade Size (Sh.) (90 D):	45

Institutional Trades
Total Institutional Trades:	20,821
Avg Institutional Trade:	$4.85M
Avg Institutional Trade (30 D):	$9.5M
Avg Institutional Trade (90 D):	$9.28M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	4

Market Closing Trades
Avg Closing Trade:	$15.6M
Avg Closing Trade (30 D):	$34.95M
Avg Closing Trade (90 D):	$33.34M
Avg Closing Volume:	207.29K

News

Jun 9, 2026 @ 6:08 PM Incyte Bets $1.25 Billion On Rare Bleeding Disorde... Source: Vandana Singh

Sep 28, 2025 @ 4:20 AM China Medical System (867.HK; 8A8.SG) Positive Res... Source: China Medical System Holdings Limited

May 27, 2025 @ 5:00 PM Liposarcoma Clinical Trial Analysis: Key Insights ... Source: Delveinsight

May 9, 2025 @ 2:46 PM Merus annonce ses résultats financiers pour le ... Source: Merus N.V.

May 7, 2025 @ 3:00 PM Generic Oncology Drugs Market Size Estimated to Re... Source: Statifacts

Financials
	TTM	Q1 2026	Q3 2025
Basic EPS		$1.52	$2.17
Diluted EPS		$1.47	$2.11
Revenue		$1.27B	$1.37B
Gross Profit		$1.17B	$1.27B
Net Income / Loss		$303.33M	$424.17M
Operating Income / Loss		$301.12M	$443.52M
Cost of Revenue		$104.52M	$99M
Net Cash Flow		$363.28M	$500.04M
PE Ratio

Splits
Sep 01, 2000	2:1